Skip to content

Clinical trials

Completed Autism Spectrum Disorder trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Autism Spectrum Disorder Status: Completed Country / region: United States Clear all

464 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20041
20051
20064
20079
20089
200918
201017
201111
201221
201328
201423
201540
201629
201727
201842
201938
202031
202142
202234
202318
202418
20253

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed464

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Massachusetts General Hospital25
Yale University18
Stanford University13
Children's Hospital Medical Center, Cincinnati12
Emory University12
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.12
Vanderbilt University Medical Center12
University of North Carolina, Chapel Hill10
Boston Children's Hospital9
University of California, Los Angeles9

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Autism Spectrum Disorder464
Autistic Disorder157
Asperger Syndrome31
Child Development Disorders, Pervasive26
Anxiety Disorders24
Attention Deficit Disorder with Hyperactivity16
Learning Disabilities14
Intellectual Disability11
Developmental Disabilities9
Fragile X Syndrome6

Trials

Showing 1 to 25 of 464. Each trial links to its page on Pharma Observatory.

364 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.